for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Collegium Pharmaceutical Inc

COLL.OQ

Latest Trade

11.33USD

Change

-0.30(-2.58%)

Volume

70,229

Today's Range

11.14

 - 

11.75

52 Week Range

10.03

 - 

19.79

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
11.63
Open
11.75
Volume
70,229
3M AVG Volume
5.78
Today's High
11.75
Today's Low
11.14
52 Week High
19.79
52 Week Low
10.03
Shares Out (MIL)
33.47
Market Cap (MIL)
389.26
Forward P/E
-32.57
Dividend (Yield %)
--

Next Event

Collegium Pharmaceutical Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Collegium Pharmaceutical Q2 Loss Per Share $0.14

Collegium Reports Q1 Loss Per Share $0.29

Collegium Reports Fourth-Quarter And Full-Year 2018 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Collegium Pharmaceutical Inc

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

Industry

Biotechnology & Drugs

Contact Info

100 Technology Center Dr

+1.781.7133699

http://www.collegiumpharma.com/

Executive Leadership

Michael Thomas Heffernan

Chairman of the Board

Joseph J. Ciaffoni

President, Chief Executive Officer, Director

Paul Brannelly

Chief Financial Officer, Executive Vice President

Alison B. Fleming

Executive Vice President, Chief Technology Officer

Shirley R. Kuhlmann

Executive Vice President, General Counsel, Secretary

Key Stats

1.67 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.3K

2019(E)

0.3K
EPS (USD)

2016

-3.880

2017

-2.470

2018

-1.190

2019(E)

-0.357
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.33
Price To Book (MRQ)
4.53
Price To Cash Flow (TTM)
11.35
Total Debt To Equity (MRQ)
13.40
LT Debt To Equity (MRQ)
11.17
Return on Investment (TTM)
-8.49
Return on Equity (TTM)
-4.48

Latest News

BRIEF-Collegium Reports Q1 Loss Per Share $0.57

* COLLEGIUM REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Collegium Appoints Shirley Kuhlmann As General Counsel

* COLLEGIUM ANNOUNCES THE APPOINTMENT OF SHIRLEY KUHLMANN AS GENERAL COUNSEL Source text for Eikon: Further company coverage:

BRIEF-Collegium Reports Q4 Loss Per Share $0.54

* COLLEGIUM REPORTS FOURTH QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Collegium To Host Conference Call To Discuss Fourth Quarter 2017 Financial Results And Provide Corporate Update

* COLLEGIUM TO HOST CONFERENCE CALL TO DISCUSS FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE Source text for Eikon: Further company coverage:

BRIEF-Collegium Filed Patent Infringement Lawsuit Against Teva Pharma USA

* COLLEGIUM PHARMA SAYS FILED PATENT INFRINGEMENT LAWSUIT IN U.S. DISTRICT COURT FOR DISTRICT OF DELAWARE AGAINST TEVA PHARMACEUTICALS USA INC

BRIEF-Janus Henderson Group Reports 10.1 Pct Passive Stake In Collegium Pharmaceutical

* JANUS HENDERSON GROUP PLC REPORTS 10.1 PERCENT PASSIVE STAKE IN COLLEGIUM PHARMACEUTICAL AS OF DEC 31, 2017 - SEC FILING Source text : [http://bit.ly/2mvIp5l] Further company coverage:

BRIEF-Depomed Announces Closing Of Nucynta Commercialization Agreement With Collegium Pharmaceutical

* DEPOMED ANNOUNCES CLOSING OF NUCYNTA COMMERCIALIZATION AGREEMENT WITH COLLEGIUM PHARMACEUTICAL

BRIEF-BioDelivery Sciences Reacquires Onsolis From Collegium Pharmaceutical

* BIODELIVERY SCIENCES REACQUIRES ONSOLIS® FROM COLLEGIUM PHARMACEUTICAL

BRIEF-Depomed Announces Nucynta® Commercialization Agreement With Collegium Pharmaceutical

* DEPOMED ANNOUNCES NUCYNTA® COMMERCIALIZATION AGREEMENT WITH COLLEGIUM PHARMACEUTICAL

BRIEF-Collegium To License Rights To Commercialize Nucynta Franchise

* COLLEGIUM TO LICENSE RIGHTS TO COMMERCIALIZE NUCYNTA FRANCHISE

BRIEF-Collegium reports third quarter loss of $0.45 per share

* Collegium reports third quarter financial results and provides corporate update

BRIEF-Collegium receives FDA approval for sNDA for Xtampza® ER

* Collegium receives FDA approval for sNDA for Xtampza® ER Source text for Eikon: Further company coverage:

BRIEF-Collegium notified that the FDA will not meet PDUFA goal date for SNDA for Xtampza ER

* Collegium notified that the FDA will not meet PDUFA goal date for SNDA for Xtampza® ER

BRIEF-Collegium reports Q2 loss per share $0.72

* Collegium reports second quarter financial results and provides corporate update

BRIEF-Collegium appoints Joseph Ciaffoni as chief operating officer

* Collegium announces the appointment of Joseph Ciaffoni as chief operating officer

BRIEF-Collegium reports Q1 loss per share $0.79

* Collegium reports first quarter financial results and provides corporate update

BRIEF-Collegium Pharmaceutical announces expanded managed care coverage

* Collegium Pharmaceutical announces expanded managed care coverage for Xtampza ER for medicare part D patients

BRIEF-Collegium Pharma enters controlled equity offering sales agreement

* Collegium Pharmaceutical Inc - entered controlled equity offering sales agreement, dated march 13, 2017 with Cantor Fitzgerald & Co - SEC filing

BRIEF-Collegium Q4 loss per share $1.02

* Collegium reports fourth quarter financial results and provides corporate update

BRIEF-Sectoral Asset Management reports 7.4 percent passive stake in Collegium Pharmaceutical as of December 31, 2016

* Sectoral Asset Management reports a 7.4 percent passive stake in Collegium Pharmaceutical as of December 31, 2016 - SEC filing Source text : [ID:http://bit.ly/2l19Bc1] Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up